Skip to content

Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)

Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02816372
Acronym
VT4ARDS
Enrollment
37
Registered
2016-06-28
Start date
2016-10-31
Completion date
2018-06-14
Last updated
2025-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Brief summary

Despite the use of protective ventilation, neuromuscular blocking agent and prone position, ARDS mortality remains high (30%-50%) in observational studies, and pneumothorax rate in randomized controlled trial remains stable (10%). The driving pressure (the ratio of tidal volume over respiratory system compliance) has recently been strongly associated with ARDS mortality, suggesting that tidal volume reduction below 6ml/kg may offer mortality benefit. While extracorporeal CO2 removal technique are currently under investigation in association with tidal volume reduction

Interventions

OTHERTidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)

Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* invasive mechanical ventilation * ARDS (Berlin definition) with PaO2/FiO2 ratio ≤ 150 mm Hg

Exclusion criteria

* Age below 18 year * planned duration of invasive mechanical ventilation \< 48 hours * ARDS criteria present for more than 24 hours * known or suspected intracranial hypertension * known or suspected COPD * chronic respiratory failure under long term oxygen or non-invasive ventilation * pneumothorax or broncho-pleural fistula * morbid obesity with body weight \>1 kg/cm height * sickle cell disease * recent bone marrow transplantation, aplasia following chemotherapy * burn injury on more than 30% of body surface * severe hepatic cirrhosis (Child-Pugh score C) * extracorporeal circulation life support * pregnancy * advance directives to withhold or withdraw life-sustaining treatment * previous inclusion in present study * patient under an exclusion period following inclusion in another biomedical study * patient deprived of freedom, minor, subject under a legal protective measure * lack of affiliation to social security as required by French regulation * lack of written informed consent by patient or next of kin

Design outcomes

Primary

MeasureTime frameDescription
Change in driving pressureBaseline and 24 hours following inclusionDriving pressure is the difference between total respiratory system plateau pressure minus total positive end-expiratory pressure (PEEP)

Secondary

MeasureTime frameDescription
Rate of patients who achieved tidal volume reduction equal to 4 ml/kg predicted body weight48 hours following inclusion
Rate of pneumothoraxDay 90
Change in right ventricule/left ventricule areaBaseline and 24 hours following inclusionEchographic measurement of right ventricule/left ventricule

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026